作者的详细信息

Поддубная, Ирина Владимировна

期	栏目	标题	文件
卷 15, 编号 1 (2013)	Articles	CUP-syndrome: the present view of the problem (a review of literature)
卷 15, 编号 2 (2013)	Articles	Prognostic value of p53 expression in patients with stage I breast cancer
卷 15, 编号 2 (2013)	Articles	Toxicity of trabectedin-based combinations in the treatment of different malignant tumors
卷 15, 编号 3 (2013)	Articles	Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii
卷 15, 编号 3 (2013)	Articles	Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii
卷 15, 编号 4 (2013)	Articles	The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer
卷 15, 编号 4 (2013)	Articles	Bone mineral density in patient with breast cancer
卷 16, 编号 1 (2014)	Articles	The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program
卷 16, 编号 4 (2014)	Articles	Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials)
卷 17, 编号 1 (2015)	Articles	Breast cancer immunology: theory and prospects (review)
卷 16, 编号 3 (2014)	Articles	Vulvar Langerhans cell histiocytosis: case report
卷 17, 编号 1 (2015)	Articles	A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian
卷 17, 编号 1 (2015)	Articles	Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience)
卷 17, 编号 3 (2015)	Articles	The results of Epidemiological HER2 screening program in patients with breast cancer in 2014
卷 17, 编号 3 (2015)	Articles	Clinical and prognostic significance of matrix metalloproteinase-7 and vascular endothelium growth factor in patients with ovarian cancer
卷 17, 编号 3 (2015)	Articles	Current understanding of the role of insulin-like and vascular endothelial growth factors in development, prognosis and targeted therapy in patients with ovarian cancer
卷 18, 编号 1 (2016)	Articles	Features of surgical treatment of patients with breast cancer receiving preoperative systemic therapy	(Rus)
卷 18, 编号 1 (2016)	Articles	Insulin-like growth factors in patients with ovarian tumors (results of own research)	(Rus)
卷 19, 编号 4 (2017)	Articles	Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0	(Rus)
卷 19, 编号 3 (2017)	Articles	Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer	(Rus)
卷 20, 编号 1 (2018)	Articles	Taxanes induced peripheral neuropathy: mechanism of development and pharmacogenetic factors	(Rus)
卷 20, 编号 3 (2018)	Articles	The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer	(Rus)
卷 20, 编号 4 (2018)	Articles	Quality control of immunohistochemical analyzes in Russia: yesterday, today, tomorrow	(Rus)
卷 20, 编号 4 (2018)	Articles	Bendamustine in the treatment of B-cell non-Hodgkin lymphoma	(Rus)
卷 21, 编号 2 (2019)	Articles	Successful experience of combined immunochemotherapy at refractory course of primary cutaneous peripheral T-cell lymphoma, unspecified	(Rus)
卷 21, 编号 1 (2019)	Articles	Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports	(Rus)
卷 21, 编号 1 (2019)	Articles	The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review)	(Rus)
卷 21, 编号 4 (2019)	CLINICAL ONCOLOGY	The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution	(Rus)
卷 22, 编号 1 (2020)	CLINICAL ONCOLOGY	Solitary (extramedullary) plasmocytoma. Clinical recommendations	(Rus)
卷 22, 编号 1 (2020)	CLINICAL ONCOLOGY	ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution	(Rus)
卷 22, 编号 1 (2020)	CLINICAL ONCOLOGY	Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer	(Rus)
卷 22, 编号 2 (2020)	Guidelines	Hodgkin's lymphoma	(Rus)
卷 22, 编号 2 (2020)	Guidelines	Follicular lymphoma	(Rus)
卷 22, 编号 2 (2020)	Conference Proceedings	Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic	(Rus)
卷 22, 编号 2 (2020)	Original Article	Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52	(Rus)
卷 22, 编号 2 (2020)	Conference Proceedings	New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas	(Rus)
卷 22, 编号 2 (2020)	Review	Accompanying therapy in oncohematological patients with secondary immunodeficiency	(Rus)
卷 22, 编号 2 (2020)	Best Practice	Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience	(Rus) (Eng)
卷 22, 编号 2 (2020)	Original Article	First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice	(Rus)
卷 22, 编号 4 (2020)	CLINICAL ONCOLOGY	Multiple myeloma	(Rus)
卷 22, 编号 4 (2020)	CLINICAL ONCOLOGY	The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review	(Rus)
卷 22, 编号 4 (2020)	CLINICAL ONCOLOGY	Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy	(Rus)
卷 23, 编号 1 (2021)	CLINICAL ONCOLOGY	Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas	(Rus)
卷 23, 编号 2 (2021)	CLINICAL ONCOLOGY	Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization	(Rus)
卷 23, 编号 3 (2021)	CLINICAL ONCOLOGY	Extrapulmonary small cell carcinoma. Literature review	(Rus)
卷 23, 编号 2 (2021)	CLINICAL ONCOLOGY	The use of erythropoietins in oncology	(Rus)
卷 23, 编号 4 (2021)	CLINICAL ONCOLOGY	Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III	(Rus)
卷 24, 编号 1 (2022)	CLINICAL ONCOLOGY	Immuno-morphological characteristics of bone marrow in patients with ovarian cancer	(Rus)
卷 24, 编号 1 (2022)	CLINICAL ONCOLOGY	Therapy of lymphoproliferative diseases in the era of COVID-19: challenges and solutions	(Rus)
卷 24, 编号 1 (2022)	CLINICAL ONCOLOGY	From the editor-in-chief of the journal "Modern Oncology" Academician of the Russian Academy of Sciences I.V. Poddubnaya	(Rus)
卷 24, 编号 1 (2022)	CLINICAL ONCOLOGY	Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study	(Rus)
卷 24, 编号 3 (2022)	CLINICAL ONCOLOGY	Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study	(Rus)
卷 24, 编号 2 (2022)	CLINICAL ONCOLOGY	Risk of discrimination against Russian citizens in providing medical care abroad as a health care trend	(Rus)
卷 24, 编号 3 (2022)	CLINICAL ONCOLOGY	The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study	(Rus)
卷 24, 编号 3 (2022)	CLINICAL ONCOLOGY	Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: Prospective cohort study	(Rus)
卷 25, 编号 1 (2023)	CLINICAL ONCOLOGY	Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study	(Rus)
卷 25, 编号 2 (2023)	CLINICAL ONCOLOGY	Heterogeneous diffuse large B-cell lymphoma: accurate diagnosis as a key to successful therapy. A review	(Rus)
卷 25, 编号 2 (2023)	CLINICAL ONCOLOGY	Challenges and perspectives of first-line therapy in patients with diffuse B-cell lymphoma: A review	(Rus)
卷 25, 编号 2 (2023)	CLINICAL ONCOLOGY	Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study	(Rus)
卷 25, 编号 3 (2023)	History of medicine	Memorial lecture to the 100th anniversary of the birth of Professor Yu.I. Lorie	(Rus)
卷 25, 编号 3 (2023)	CLINICAL ONCOLOGY	Diffuse large B-cell lymphoma: strokes to the epidemiological portrait. A review	(Rus)
卷 25, 编号 3 (2023)	CLINICAL ONCOLOGY	An interdisciplinary approach to the management of oncohematological patients with immunodeficiency: clinical cases. A review	(Rus)
卷 25, 编号 4 (2023)	CLINICAL ONCOLOGY	Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas?	(Rus)
卷 25, 编号 4 (2023)	CLINICAL ONCOLOGY	Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study	(Rus)
卷 26, 编号 2 (2024)	Articles	Immunohistochemical factors of prognosis of immunotherapy for metastatic melanoma: А prospective and retrospective study	(Rus)
卷 26, 编号 3 (2024)	Articles	Role of immunohistochemical prognostic factors in various types of immunotherapy for metastatic melanoma: A retro-prospective study	(Rus)
卷 26, 编号 3 (2024)	Articles	Clinical significance of PET/CT in the diagnosis of primary adrenal malignancies	(Rus)
卷 26, 编号 4 (2024)	Articles	Peritoneal lymphomatosis as the only manifestation of diffuse B-cell large cell lymphoma: A clinical case	(Rus)
卷 27, 编号 1 (2025)	Articles	Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study	(Rus)

用户名
密码
记住我

忘记您的密码?	注册

用户名
密码
记住我

忘记您的密码?	注册